Literature DB >> 6179186

The significance of coronary topography for operative technique and tactics in multiple myocardial revascularization with jump-grafts.

E M Eschenbruch, F Pabst, P Tollenaere, H Roskamm, M Schmuziger.   

Abstract

Aortocoronary bypass procedures for proximal lesions are accepted with widely documented excellent results, but are still controversial in their application for diffuse disease. However, failures of the single graft technique to small coronary branches with marginal flows are markedly reduced by the jump technique. In our experience with 447 angiographic controls from April 1978 to December 1980, the jump-graft patency rate was 87.8% versus 84.9% for single grafts, and as high as 96.3% in the subgroup of multiple jumps (sequential grafts). The sequence of the anastomoses as far as the individual flow is concerned significantly influences the results of the jump-graft technique.

Mesh:

Year:  1981        PMID: 6179186     DOI: 10.1055/s-2007-1023478

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  3 in total

1.  How serious is a proximal occlusion of a posterolateral sequential bypass?

Authors:  J T Christenson; M Schmuziger
Journal:  Tex Heart Inst J       Date:  1996

2.  Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV trial.

Authors:  Rajendra H Mehta; T Bruce Ferguson; Renato D Lopes; Gail E Hafley; Michael J Mack; Nicholas T Kouchoukos; C Michael Gibson; Robert A Harrington; Robert M Califf; Eric D Peterson; John H Alexander
Journal:  Circulation       Date:  2011-06-27       Impact factor: 29.690

3.  Patency and adverse outcomes of sequential vs. individual saphenous vein grafts in coronary artery bypass: A meta-analysis.

Authors:  He Jiao; Jinghui Li; Yunpeng Bai; Zhigang Guo
Journal:  Front Cardiovasc Med       Date:  2022-07-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.